Int J Food Sci Nutr. 2015; 66 (6): 611–622.
28. Keys A. Coronary heart disease in seven countries. 1970. Nutrition. 1997 Mar 13; 13 (3): 250–252; discussion 49, 3.
29. Keys A. Mediterranean diet and public health: personal reflections. Am J Clin Nutr. 1995 Jun; 61 (6 Suppl): 1321s–1323s.
30. Там же.
31. Dias CB, Garg R, Wood LG, et al. Saturated fat consumption may not be the main cause of increased blood lipid levels. Med Hypotheses. 2014 Feb; 82 (2): 187–195.
32. Yano K, Rhoads GG, Kagan A, et al. Dietary intake and the risk of coronary heart disease in Japanese men living in Hawaii. Am J Clin Nutr. 1978 Jul; 31 (7): 1270–1279.
33. Там же.
34. Keys A, Kimura N, Kusukawa A, et al. Lessons from serum cholesterol studies in Japan, Hawaii and Los Angeles. Ann Intern Med. 1958 Jan 1; 48 (1): 83–94.
35. Parodi PW. Has the association between saturated fatty acids, serum cholesterol and coronary heart disease been over emphasized? Int Dairy J. 2009 Jun Jul; 19 (6–7): 345–361.
36. Там же.
37. Там же.
38. Там же.
39. Там же.
40. Campos H, Blijlevens E, McNamara JR, et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb. 1992 Dec; 12 (1): 1410–1419.
41. Dreon DM, Fernstrom HA, Campos H, et al. Change in dietary saturated fat intake is correlated with change in mass of large low-density-lipoprotein particles in men. Am J Clin Nutr. 1998 May; 67 (5): 828–836.
42. Parodi PW. Has the association between saturated fatty acids, serum cholesterol and coronary heart disease been over emphasized? Int Dairy J. 2009 (Jun Jul; 19 (6–7): 345–361.
43. Там же.
44. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM, 2006 Jan; 99 (1): 1–14.
45. Dreon DM, Fernstrom HA, Williams PT, et al. A very low-fat diet is not associated with improved lipoprotein profiles in men with a predominance of large, low-density lipoproteins. Am J Clin Nutr. 1999 Mar; 69 (3): 411–418.
46. Turpeinen O, Karvonen MJ, Pekkarinen M, et al. Dietary prevention of coronary heart disease: the Finnish Mental Hospital Study. Int J Epidemiol. 1979 Jun; 8 (2): 99–118.
47. Parodi PW. Has the association between saturated fatty acids, serum cholesterol and coronary heart disease been over emphasized? Int Dairy J. 2009 Jun-Jul; 19 (6–7): 345–361.
48. Dayton S, Pearce ML. Diet high in unsaturated fat. A controlled clinical trial. Minn Med. 1969 Aug; 52 (8): 1237–1242.
49. Loffredo L, Perri L, Di Castelnuovo A, et al. Supplementation with vitamin E alone is associated with reduced myocardial infarction: a meta-analysis. Nutr Metab Cardiovasc Dis. 2015 Apr; 25 (4): 354–363.
50. Ramsden CE, Hibbeln JR, Majchrzak SF, et al. n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr. 2010 Dec; 104 (11): 1586–1600.
51. Там же.
52. Frantz ID Jr., Dawson EA, Ashman PL, et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis. 1989 Jan-Feb; 9 (1): 129–135.
53. Baum SJ, Kris-Etherton PM, Willett WC, et al. Fatty acids in cardiovascular health and disease: a comprehensive update. J Clin Lipidol. 2012 May-Jun; 6 (3): 216–234.
54. Christakis G, Rinzler SH, Archer M, et al. Effect of the Anti-Coronary Club program on coronary heart disease. Risk-factor status. JAMA. 1966 Nov 7; 198 (6): 597–604.
55. DiNicolantonio JJ. The cardiometabolic consequences of replacing saturated fats with carbohydrates or Ω-6 polyunsaturated fats: Do the dietary guidelines have it wrong? Open Heart, 2014 Feb 8;1(1):e000032. doi:10.1136/openhrt-2013-000032.
56. Christakis G, Rinzler SH, Archer M, et al. The anti-coronary club. A dietary approach to the prevention of coronary heart disease – a seven-year report. Am J Public Health Nations Health. 1966 Feb; 56 (2): 299–314.
57. Rose GA, Thomson WB, Williams RT. Corn oil in treatment of ischaemic heart disease. Br Med J. 1965 Jun 12; 1 (5449): 1531–1533.
58. Там же.
59. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999 Feb 16; 99 (6): 779–785.
60. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acidrich diet in secondary prevention of coronary heart disease. Lancet. 1994 Jun 11; 343 (8911): 1454–1459.
61. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr 4; 368 (14): 1279–1290.
62. de Lorgeril M, Salen P, Defaye P, et al. Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med. 2013; 11: 5.
63. DiNicolantonio JJ, Niazi AK, McCarty MF, et al. Omega-3s and cardiovascular health. Ochsner J. 2014 Fal l; 14 (3): 399–412.
64. DiNicolantonio JJ, Niazi AK, O’Keefe JH, Lavie CJ. Explaining the recent fish oil trial “failures”. J Glycomics Lipidomics. 2013; 3 (1): e112. doi:10.4172/2153-0637.1000e112.
65. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet. 1989 Sep 30; 2 (8666): 757–761.
66. Burr ML, Sweetham PM, Fehily AM. Diet and reinfarction. Eur Heart J. 1994 Aug; 15 (8): 1152–1153.
67. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002 Apr 23; 105 (16): 1897–1903.
68. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999 Aug 7; 354 (9177): 447–455.
69. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Oct 4; 372 (9645): 1223–1230.
70. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007 Mar 31; 369 (9567): 1090–1098.
71. Там же.
72. Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008 Jul; 39 (7): 2052–2058.
73. Einvik G, Klemsdal TO, Sandvik L, et al. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil. 2010 Oct; 17 (5): 588–592.
74. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002 Oct; 56 (8): 365–379.
75. DiNicolantonio JJ, Meier P, O’Keefe JH. Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter? Mo Med. 2013 Nov-Dec; 110 (6): 495–498.
76. Simopoulos AP, Leaf A, Salem N Jr. Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. Ann Nutr Metab. 1999; 43 (2): 127–130.
77. Harris WS, Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med. 2004 Jul; 39 (1): 212–220.
1. Lee KW, Lee HJ, Cho HY, et al. Role of the conjugated linoleic acid in the prevention of cancer. Crit Rev Food Sci Nutr. 2005; 45 (2): 135–144.
2. Wang Y, Lu J, Ruth MR, et al. Trans-11 vaccenic acid dietary supplementation induces hypolipidemic effects in JCR: LA-cp rats. J Nutr. 2008 Nov; 138 (1): 2117–2122.
3. Micha R, Mozaffarian D. Trans fatty acids: effects on cardiometabolic health and implications for policy. Prostaglandins Leukot Essent Fatty Acids. 2008; 79 (3–5): 147–152.
4. Kinsella JE, Bruckner G, Mai J, et al. Metabolism of trans fatty acids with emphasis on the effects of trans, trans-octadecadienoate on lipid composition, essential fatty acid, and prostaglandins: an overview. Am J Clin Nutr. 1981 Oct; 34 (1): 2307–2318.
5. Tardy AL, Morio B, Chardigny JM, et al. Ruminant and industrial sources of trans-fat and cardiovascular and diabetic diseases. Nut Res Rev. 2011 Jun; 24 (1): 111–117.
6. Morris MC, Evans DA, Bienias JL, et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol. 2003 Feb; 60 (2): 194–200.
7. Chavarro JE, Stampfer MJ, Campos H, et al. A prospective study of trans-fatty acid levels in blood and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17 (1): 95–101.
8. Chajes V, Thiebaut AC, Rotival M, et al. Association between serum transmonounsaturated fatty acids and breast cancer risk in the E3N-EPIC Study. Am J Epidemiol. 2008 Jun 1; 167 (11): 1312–1320.
9. Phivilay A, Julien C, Tremblay C, et al. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer’s disease.